Unless the following excerpts are meant to include psoriasis:
"...and an exploratory, dose-ranging Phase 2 study."
"Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis, psoriasis or with autoimmune uveitis."
"Illegitimacy is something we should talk about in terms of not having it."
- Dan Quayle